TB activists call for the disease to be made a political priority in the country and demand multisectoral departmental accountability.

Many TB medicines and formulations accessible in lower- and middle-income countries remain unaffordable or unavailable in Europe.

Besides preventing illness and death, TB preventive treatment (TPT) is estimated to be highly cost-effective. Yet, uptake of TPT is not what it could be in South Africa. Tiyese Jeranji asks how much has changed since the Department of Health last year decided to make TPT much more widely available.

WHO publishes the report of the second meeting of PADO-TB2 group providing an updated list of priorities for paediatric formulations of TB medicines.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Mike Frick, TAG TB Project Co-Director, delivered comments as a civil society representative at the WHO Director-General’s TB Vaccine Accelerator Council meeting in Geneva, Switzerland. 

First-ever International leadership summit of medical associations on achieving UN High-Level Meeting targets to end TB concludes with the Kochi Declaration.

The World Health Organization (WHO) will host a global webinar on 5 June 2024 on its newly-released guidance on conducting reviews of TB programs and undertaking TB epidemiological reviews and assessments of TB surveillance and vital registration systems.

The World Health Organization (WHO) plans to update its guidance on use of interferon-gamma release assays (IGRAs) for the detection of TB infection. The aim of the update is to compare new (index) IGRAs with the IGRAs currently recommended by WHO (reference tests) for the diagnosis of TB infection.

A limited amount of travel and registration support (participant support) is available for participants planning to attend the 7th Global Forum on TB Vaccines to be held on 8-10 October 2024 in Rio de Janiero, Brazil. Participant support is available for students, post-docs, early career researchers, advocates, affected communities, and participants from lower- and middle-income countries.